For full-year 2018 the firm's revenues rose 38 percent to $21.9 million from $15.9 million a year ago.
In addition, a German court found in December that German NIPT company Cenata infringes Streck's patent.
The researchers found evidence of genetic continuity in Anatolia, even as the subsistence strategy changed from hunting and gathering to farming.
The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions.
The company said it will offer 2.5 million shares, while stockholder Clarus Lifesciences will sell another 2 million shares in the offering.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.
The companies will initially work on a shotgun metagenomic sequencing-based service for microbiome research that will be offered internationally.
The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.
Through this analysis, the researchers uncovered borders between active and repressed chromatin that varied by cell type.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
Ambry researchers recently published a study suggesting that roughly 40 percent of genetic variants reported in raw data from DTC genetic tests may be wrong.
Last week, GenomeWeb's readers were most interested in Donald Trump's proposed 12 percent decrease in funding to the National Institutes of Health in 2020.
The deal will enable the Australian firm to distribute its diagnostic tests in the United Arab Emirates, Saudi Arabia, Bahrain, Qatar, and Oman.
LUNGevity will promote the donation of excess lung cancer tissue and fluid samples to boost the Broad's efforts to develop next-generation research models.
This week's news includes Danaher, PredictImmune, Servier Group, Cadex Genomics, and Kiyatc.
The program's participant center at the Scripps Research Translational Institute is planning to test different modules for returning results.
An epigenome-wide association study in women with opioid dependence led to hypomethylated sites in three genes involved in various cellular processes.
UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.
DermTech develops diagnostics for skin cancer and other skin diseases, and provides molecular pathology services through its CLIA-certified lab.
Last month, the company said it was planning a $7.5 million public offering of 6.25 million shares and warrants for another 6.25 million shares.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.